

## Invitation to Participate in the Pediatric Isavuconazole Registry (Ped-IR)



Dear colleagues,

On behalf of the International FungiScope® Pediatric Team, we are pleased to invite your clinical site to participate in a global, retrospective observational study:

### **Isavuconazole for Treatment of Proven, Probable or Possible Invasive Mold Disease in Pediatric Patients: A Retrospective Multinational Study (Ped-IR).**

This FungiScope® coordinated study aims to generate real-world evidence on the safety and effectiveness of isavuconazole in pediatric patients treated from **January 1, 2024 onwards**.

#### **Objectives**

Despite recent regulatory approvals of isavuconazole for children, there remains a paucity of real-world paediatric data on the safety and effectiveness especially among immunocompromised populations. This study aims to:

- Describe the real-world use, dosing patterns, safety profile, and clinical outcomes of isavuconazole in pediatric patients with invasive mold disease.
- Generate evidence that informs clinical decision-making and future guideline development in pediatric antifungal therapy.
- Support international harmonization of antifungal stewardship practices in children.

#### **Key Study Information:**

- **Design:** Retrospective, multicentre, multinational
- **Population:** Pediatric patients <18 years at treatment start of isavuconazole for possible/probable/proven invasive mold infections (as per 2020 EORTC/MSG criteria)
- **Study Period:** Patients started on isavuconazole treatment on **January 1st, 2024 or later**
- **Data Collection:** Fully anonymized eCRF (demographics, underlying disease, indication, dosing regimen, adverse events, outcomes)
- **Estimated contribution time:** approx. 30–45 minutes per patient
- **Interventions: None; no biological sampling required**
- **Ethicals:** Local ethics approval as per national requirements
- Contributors will be acknowledged with authorship in resulting publications

## Next Steps

Pediatric hematology/oncology, infectious diseases, and transplant centres with eligible cases are welcome to participate. Upon interest, we will provide the full protocol, eCRF, and ethics documents.

For questions or to express interest, please contact:

Prof. Zoi Pana and Dr. Danila Seidel: [panazoi@gmail.com](mailto:panazoi@gmail.com); [danila.seidel@uk-koeln.de](mailto:danila.seidel@uk-koeln.de)

We would be delighted to collaborate with you in this international effort to improve outcomes for children with invasive fungal diseases.

Warm regards,

Zoi-Dorothea Pana, Cyprus, Greece

Sarina Butzer, Germany

Thanasis Tragiannidis, Greece

Andreas Groll, Germany

Thomas Lehrnbecher, Germany

Luise Martin, Germany

Daniel Ebrahimi-Fakhari, Germany

Oliver Cornely, Germany

Fabianne Carlesse, Brazil

Adilia Warris, UK

Danila Seidel, Germany